

DEPARTMENTS

236 Reflections

A New Look at the Xanthine Alkaloids
Stanley Scheindlin

243 Nascent Transcripts

Emerging concepts from the recent literature

244 Significant Deciles

ASPET celebrates its centennial anniversary

271 Beyond the Bench

Sex, Lies, and Phlogiston
Christie Carrico

273 NetResults

Sites of Interest on the World Wide Web

274 Professional Opportunities

Position Openings

281 On Deck

Upcoming Meetings

284 Outliers

mi cartoon

EDITOR

Harry B. Smith

ASSOCIATE EDITOR

John W. Nelson

DESIGN & LAYOUT

Vizuál, Inc.

EDITORIAL ADVISORY BOARD

John S. Lazo, Chair, *U Pittsburgh*
Darrell R. Abernethy, *NIH/NIA*
Susan Amara, *U Pittsburgh*
Leslie Z. Benet, *UCSF*
Joan Heller Brown, *UCSD*
Bryan Cox, *Abbott*
Raymond Dingleline, *Emory U*
Sue Duckles, *UC Irvine*
Alfred G. Gilman, *U Texas SW*
Randy Hall, *Emory U*
Ken Harden, *U North Carolina*
John Hickman, *Servier*
Dayle Houston*, *U North Carolina*
Robert S. Kass, *Columbia U*
Serrine S. Lau, *U Arizona*
Rochelle Long, *NIGMS/NIH*
Benedict Lucchesi, *U Michigan*
Kenneth P. Minneman, *Emory U*
Perry Molinoff, *U Pennsylvania*
Richard R. Neubig, *U Michigan*
Stefan Offermanns, *U Heidelberg*
Carlo Patrono, *U Rome*
David Roman**, *U Michigan*
Alan Sartorelli, *Yale U*
Boris Tabakoff, *U Colorado*
Palmer Taylor, *U San Diego*
Robert Tomko*, *U Pittsburgh*
Ted Torphy, *Johnson&Johnson*
Roger Tsien, *UCSD*
Michael R. Vasko, *U Indiana*
Mary Vore, *U Kentucky*
Richard M. Weinsilboum, *Mayo*

* Student representative; ** Postdoctoral representative

BOARD OF PUBLICATIONS TRUSTEES

Brian M. Cox
Darrell R. Abernethy
P. Jeffrey Conn
Lorraine Gudas
Eric F. Johnson
John S. Lazo
Edward T. Morgan
Richard R. Neubig
Rick G. Schnellmann
Darryle D. Schoepp
Mary Vore

EXECUTIVE OFFICER

Christine K. Carrico

JOURNALS DIRECTOR

Richard Dodenhoff

Molecular Interventions (ISSN 1534-0384) is published by the American Society for Pharmacology and Experimental Therapeutics, 9650 Rockville Pike, Bethesda, MD 20814-3995. Published bimonthly in February, April, June, August, October, and December. Annual subscription rates: U.S.: \$240 for institutions; and \$78 for individuals. Outside the U.S.: \$261 for institutions and \$99 for individuals. The subscription price to ASPET members (\$30) is included in membership dues. Single issue: \$44. Subscriptions include access to the online version of *MI* at molinterv.org (ISSN 1543-2548). Indexed or abstracted by Biochemistry & Biophysics Citation Index, EMBASE/Excerpta Medica, Index to Scientific Reviews, ISI Alerting Services, ISI Web of Science, PubMed/Medline, and Science Citation Index-Expanded.

Advertising (FASEB AdNet): 301-634-7103; adnet@faseb.org.
Editorial: 301-634-7790; mi@aspet.org. **Subscriptions:** 301-634-7099; staff@dues.faseb.org. **ASPET:** 301-634-7099; info@aspet.org.

Statements and opinions contained in the articles of *Molecular Interventions* are solely those of the individual authors and contributors and not of the American Society for Pharmacology and Experimental Therapeutics. The appearance of advertisements in *Molecular Interventions* is not a warranty, endorsement, or approval of the products or their safety. The American Society for Pharmacology and Experimental Therapeutics disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in the articles or advertisements.

Molecular Interventions is copyrighted by the American Society for Pharmacology and Experimental Therapeutics. Photocopying of articles beyond that permitted by Sections 107 or 108 of the U.S. Copyright Law is allowed, provided that the \$20.00 per-copy fee is paid through the Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923. Classroom photocopying is permitted at no fee, provided that students are not charged more than the cost of duplication. This consent does not extend to other kinds of copying. Reproduction of any portion of an article for subsequent republication requires permission of the copyright owner. Write to ASPET Copyright Dept., 9650 Rockville Pike, Bethesda, MD 20814-3995.


Postmaster: Send address changes to *Molecular Interventions*, ASPET, 9650 Rockville Pike, Bethesda, MD 20814-3995.

molecular interventions

pharmacological perspectives from biology, chemistry and genomics

VIEWPOINTS

246 Cdk5 in Memory: The Good and Bad of It



page 246
"Burnt-out Ends of
Smokey Days"?

In the adult brain, cyclin-dependent kinase 5 (Cdk5) can be beneficial by contributing to memory formation or can be detrimental by causing neurodegeneration, and it is of great interest to understand this dichotomy. Currently, it remains largely unknown which mechanisms are regulated by Cdk5. Recent studies by Hawasli et al. and Qu et al., however, are significant advances towards mechanistic insights. Hawasli et al. demonstrate that Cdk5 regulates protease-directed degradation of an important synaptic receptor, which impacts memory formation. Qu et al. show that Cdk5 inhibits the activity of an enzyme that metabolizes reactive oxygen species, which then leads to neurodegeneration. These two studies hold promise for establishing treatments to prevent cognitive dysfunction and neurodegeneration.

Karl Peter Giese


249 Regeneration: Bringing Together Different Disciplines

Research into tissue repair and regeneration is fought on many fronts. This article emphasizes that research into therapeutic tissue regeneration depends on diverse concepts and approaches. The interface between classical animal models, such as invertebrates and newts, and new opportunities, such as those afforded by mammalian stem cells, is in many respects unexpected. But this interface may make a reality of medicine's long-held dreams for tissue regeneration and organ replacement.

Panagiotis A. Tsonis



page 249
Of stem cells, scaffolding, and
dedifferentiation



REVIEWS

251 Development of Diversity among Drug Families: No Snail's Pace

Predatory cone snails (genus *Conus*) produce a rich array of venoms that collectively contain an estimated 100,000 small, disulfide-rich peptides (i.e., conotoxins, or conopeptides). Over the last few decades, the conopeptides have revealed a remarkable diversity of pharmacological function and utility. An evolutionary rationale for the existence of such a large and pharmacologically diverse set of gene products can be premised on the complexity of intra- and interspecies interactions that define the ecology of *Conus* snails. Insights into these evolutionary trends, moreover, have been exploited with great neuropharmacological success, so that research into the *Conus* snails effectively recapitulates a new concerted discovery approach, which we discuss here, for developing unique ligands for both laboratory and therapeutic applications. The *Conus* peptides thus serve as a model system for reaping the pharmacological potential of biodiverse animal lineages.




page 251
Reaping the rewards of natural products

Baldomero M. Olivera and Russell W. Teichert

261 After Amyloid β : Integrative Approaches to Improved Alzheimer Disease Research

The precise pathological events that cause cognitive deficits in Alzheimer disease remain to be determined. The most widely held view is that accumulation of amyloid β peptide initiates the disease process; however, with more



page 261
More to Alzheimer disease than amyloid β

than eighteen amyloid-based therapeutic candidates currently in clinical trials, the targeting of amyloid alone may not be sufficient to improve functional deficits over the course of the disease. Alternative targets, such as the tau protein and apolipoprotein E, have thus been increasingly investigated, and in the future, therapeutic strategies will likely address events that are upstream of a more broadly construed pathological cascade that includes but is not limited to the generation and accumulation of amyloid β . Consideration of such events lays the basis for an "indirect amyloid hypothesis," for which data are beginning to emerge. Although it is clinically defined by simple post-mortem criteria, Alzheimer disease likely has a complex etiology, and effective treatments for this disease will become ever more urgent as the world's population ages.

Guy R. Seabrook, William J. Ray, Mark Shearman, and Michael Hutton